Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles

Current Alzheimer Research

Volumn 8, Issue 3, 2011, Pages 303-312

  Lesser, G T ^a,b   Beeri, M S ^a   Schmeidler, J ^a   Purohit, D P ^a   Haroutunian, V ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Jewish Home Lifecare ^*  (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; APOE 4; Cholesterol; Elderly subjects; Neuritic plaques; Neurofibrillary tangles; Serum lipids

Indexed keywords

APOLIPOPROTEIN E4; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ALLELE; ALLOCORTEX; ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOCORTEX; NEUROFIBRILLARY TANGLE; NURSING HOME PATIENT; PRIORITY JOURNAL; SENILE PLAQUE;

AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID;

EID: 79956282176     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511795563755     Document Type: Article

References (104)

1. Borroni B, Grassi M, Costanzi C, Archetti S, Caimi L, Padovani A. APOE genotype and cholesterol levels in lewy body dementia and Alzheimer disease: investigating genotype-phenotype effect on disease risk. Am J Geriatr Psychiatry 14: 1022-1031 (2006).
2. Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 54: 240-242 (2000).
3. Hall K, Murrell J, Ogunniyi A, Deeg M, Baiyewu O, Gao S, et al. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology 66: 223-227 (2006).
4. Li L, Cao D, Desmond R, Rahman A, Lah JJ, Levey AI, et al. Cognitive Performance and Plasma Levels of Homocysteine, Vitamin B(12), Folate and Lipids in Patients with Alzheimer Disease. Dement Geriatr Cogn Disord 26: 384-390 (2008)
5. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59: 378-384 (2002).
6. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66: 343-348 (2009).
7. Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR. Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Miscellaneous Article. Neurology 62: 1869-1871 (2004).
8. Li G, Shofer JB, Kukull WA, Peskind ER, Tsuang DW, Breitner JC, et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 65: 1045-1050 (2005).
9. Reitz C, Tang MX, Manly J, Schupf N, Mayeux R, Luchsinger JA. Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord 25: 232-237 (2008).
10. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 315: 1045-1049 (1997).
11. Solfrizzi V, Panza F, D'Introno A, Colacicco AM, Capurso C, Basile AM, et al. Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease. J Neurol Neurosurg Psychiatry 72: 732-736 (2002).
12. Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64: 1689-1695 (2005).
13. Peters R, Poulter R, Beckett N, Forette F, Fagard R, Potter J, et al. Cardiovascular and biochemical risk factors for incident dementia in the Hypertension in the Very Elderly Trial. J Hypertens 27: 2055-2062 (2009).
14. Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence. Acta Neurol Scand Suppl 185: 50-57 (2006).
15. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, et al. Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta 364: 91-112 (2006).
16. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry 16: 343-354 (2008).
17. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 337: 1667-1674 (1997).
18. Hachinski V. Shifts in thinking about dementia. JAMA 300: 2172-2173 (2008).
19. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58: 376-388 (1999).
20. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 51: 888-895 (1994).
21. White L, Small BJ, Petrovitch H, Ross GW, Masaki K, Abbott RD, et al. Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. J Geriatr Psychiatry Neurol 18: 224-227 (2005).
22. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66: 1837-1844 (2006).
23. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.[see comment]. Lancet neurol 6: 734-746 (2007).
24. Galvin JE, Powlishta KK, Wilkins K, McKeel DW. Jr. Xiong C, Grant E, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol 62: 758-765 (2005).
25. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 357: 169-175 (2001).
26. Polvikoski T, Sulkava R, Myllykangas L, Notkola IL, Niinisto L, Verkkoniemi A, et al. Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. Neurology 56: 1690-1696 (2001).
27. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 252: 711-715 (1998).
28. Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 57: 1447-1452 (2001).
29. Lesser G, Kandiah K, Libow LS, Likourezos A, Breuer B, Marin D, et al. Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease. Dement Geriatr Cogn Disord 12: 138-145 (2001).
30. Lesser GT, Haroutunian V, Purohit DP, Schnaider Beeri M, Schmeidler J, Honkanen L, et al. Serum Lipids Are Related to Alzheimer's Pathology in Nursing Home Residents. Dement Geriatr Cogn Disord 27: 42-49 (2009).
31. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61: 199-205 (2003).
32. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486 (1991).
33. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291: 451-459 (2004).
34. Iribarren C, Reed DM, Chen R, Yano K, Dwyer JH. Low serum cholesterol and mortality. Which is the cause and which is the effect? Circulation 92: 2396-2403 (1995).
35. Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, Lantz M, et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol 55: 1185-1191 (1998).
36. Haroutunian V, Schnaider-Beeri M, Schmeidler J, Wysocki M, Purohit DP, Perl DP, et al. Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol 65: 1211-1217 (2008).
37. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, et al. Age, neuropathology, and dementia. N Engl J Med 360: 2302-2309 (2009).
38. Meng X, Rosenthal R, Rubin DB. Comparing correlated correlation coefficients. Psychol Bull 111: 172-175 (1992).
39. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43: 2412-2414 (1993).
40. Petrovitch H, Ross GW, He Q, Uyehara-Lock J, Markesbery W, Davis D, et al. Characterization of Japanese-American men with a single neocortical AD lesion type. Neurobiol Aging 29: 1448-1455 (2008).
41. Giannakopoulos P, Hof PR, Mottier S, Michel JP, Bouras C. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol (Berl) 87: 456-468 (1994).
42. Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75: 764-770 (2010).
43. Yip AG, McKee AC, Green RC, Wells J, Young H, Cupples LA, et al. APOE, vascular pathology, and the AD brain. Neurology 65: 259-265 (2005).
44. Olichney JM, Hansen LA, Galasko D, Saitoh T, Hofstetter CR, Katzman R, et al. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 47: 190-196 (1996).
45. Haroutunian V, Purohit DP, Perl DP, Marin D, Khan K, Lantz M, et al. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol 56: 713-718 (1999).
46. Anderton BH. Changes in the ageing brain in health and disease. Philos Trans R Soc Lond B Biol Sci 352: 1781-1792 (1997).
47. Price JL, Morris JC. Tangles and plaques in nondemented aging and preclinical Alzheimer's disease. Ann Neurol 45: 358-368 (1999).
48. Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex 4: 138-150 (1994).
49. Bennett DA, Wilson RS, Schneider JA, Evans DA, Mendes de Leon CF, Arnold SE, et al. Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 60: 1909-1915 (2003).
50. Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72: 1487-1494 (2009).
51. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67: 122-131 (2010).
52. Wisniewski T, Lalowski M, Golabek A, Vogel T, Frangione B. Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 345: 956-958 (1995).
53. Gomez-Isla T, West HL, Rebeck GW, Harr SD, Growdon JH, Locascio JJ, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 39: 62-70 (1996).
54. Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 69: 757-761 (1995).
55. Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology 60: 246-252 (2003).
56. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71: 344-350 (2008).
57. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80: 13-17 (2009).
58. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 73: 674-680 (2009).
59. Masse I, Bordet R, Deplanque D, Al Khedr A, Richard F, Libersa C, et al. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 76: 1624-1629 (2005).
60. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69: 878-885 (2007).
61. Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70: 1795-1802 (2008).
62. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev (2): CD003160 (2009).
63. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623-1630 (2002).
64. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22 (2002).
65. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74: 956-964 (2010).
66. Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis 21: 95-102 (2010).
67. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 64: 494-500 (2005).
68. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, et al. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol (Berl) 113: 13-21 (2007).
69. Bergmann C, Sano M. Cardiac risk factors and potential treatments in Alzheimer's disease. Neurol Res 28: 595-604 (2006).
70. Breteler MM, Bots ML, Ott A, Hofman A. Risk factors for vascular disease and dementia. Haemostasis 28: 167-173 (1998).
71. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 66: 300-305 (2009).
72. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363: 1139-1146 (2004).
73. Beeri MS, Rapp M, Silverman JM, Schmeidler J, Grossman HT, Fallon JT, et al. Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology 66: 1399-1404 (2006).
74. Dickstein DL, Walsh J, Brautigam H, Stockton SD. Jr. Gandy S, Hof PR. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 77: 82-102 (2010).
75. Launer LJ, Petrovitch H, Ross GW, Markesbery W, White LR. AD brain pathology: vascular origins? Results from the HAAS autopsy study. Neurobiol Aging 29: 1587-1590 (2008).
76. Carter CJ. Convergence of genes implicated in Alzheimer's disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem Int 50: 12-38 (2007).
77. Shobab LA, Hsiung GY, Feldman HH. Cholesterol in Alzheimer's disease.[erratum appears in Lancet Neurol. 2006 Jan;5(1):21]. Lancet neurol 4: 841-852 (2005).
78. Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 4: 191-197 (2007).
79. Wollmer MA. Cholesterol-related genes in Alzheimer's disease. Biochim Biophys Acta 1801: 762-773 (2010).
80. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 26: 355-361 (2005).
81. Reid PC, Urano Y, Kodama T, Hamakubo T. Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 11: 383-392 (2007).
82. Grimm MO, Grimm HS, Tomic I, Beyreuther K, Hartmann T, Bergmann C. Independent inhibition of Alzheimer disease betaand gamma-secretase cleavage by lowered cholesterol levels. J Biol Chem 283: 11302-11311 (2008).
83. Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, et al. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis 29: 422-437 (2008).
84. Petanceska SS, DeRosa S, Sharma A, Diaz N, Duff K, Tint SG, et al. Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Mol Neurosci 20: 395-406 (2003).
85. Panchal M, Loeper J, Cossec JC, Perruchini C, Lazar A, Pompon D, et al. Enrichment of cholesterol in microdissected Alzheimer's disease senile plaques as assessed by mass spectrometry. J Lipid Res 51: 598-605 (2010).
86. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. erratum appears in Neurobiol Dis 2000 Dec;7(6 Pt B):690. Neurobiol Dis 7: 321-331 (2000).
87. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus. Brain Res 1318: 167-177 (2010).
88. Kosicek M, Malnar M, Goate A, Hecimovic S. Cholesterol accumulation in Niemann Pick type C (NPC) model cells causes a shift in APP localization to lipid rafts. Biochem Biophys Res Commun 393: 404-409 (2010).
89. Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, et al. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem 280: 25892-25900 (2005).
90. Elder GA, Cho JY, English DF, Franciosi S, Schmeidler J, Sosa MA, et al. Elevated plasma cholesterol does not affect brain Abeta in mice lacking the low-density lipoprotein receptor. J Neurochem 102: 1220-1231 (2007).
91. Ghribi O. Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. J Alzheimers Dis 15: 673-684 (2008).
92. Chen X, Wagener JF, Morgan DH, Hui L, Ghribi O, Geiger JD. Endolysosome Mechanisms Associated with Alzheimer's Diseaselike Pathology in Rabbits Ingesting Cholesterol-Enriched Diet. J Alzheimers Dis 22: 1289-1303 (2010).
93. Ronald JA, Chen Y, Bernas L, Kitzler HH, Rogers KA, Hegele RA, et al. Clinical field-strength MRI of amyloid plaques induced by low-level cholesterol feeding in rabbits. Brain 132: 1346-1354 (2009).
94. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. Increased expression of RXRalpha in dementia: an early harbinger for the cholesterol dyshomeostasis? Mol Neurodegener 5: 36 (2010).
95. Bjorkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U. Oxysterols and Alzheimer's disease. Acta Neurol Scand Suppl 185: 43-49 (2006).
96. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13: 1029-1031 (2007).
97. Chaney MO, Baudry J, Esh C, Childress J, Luehrs DC, Kokjohn TA, et al. A beta, aging, and Alzheimer's disease: a tale, models, and hypotheses. Neurol Res 25: 581-589 (2003).
98. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease - systematic review and meta-analysis. Neurobiol Aging 30: 337-352 (2009)
99. Palmer AM. The role of the blood-CNS barrier in CNS disorders and their treatment. Neurobiol Dis 37: 3-12 (2010).
100. Ghribi O, Golovko MY, Larsen B, Schrag M, Murphy EJ. Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J Neurochem 99: 438-449 (2006).
101. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 11: 721-736 (2006).
102. Vestergaard M, Hamada T, Morita M, Takagi M. Cholesterol, lipids, amyloid Beta, and Alzheimer's. Curr Alzheimer Res 7: 262-270 (2010).
103. Stefani M, Liguri G. Cholesterol in Alzheimer's disease: unresolved questions. Curr Alzheimer Res 6: 15-29 (2009).
104. Liu JP, Tang Y, Zhou S, Toh BH, McLean C, Li H. Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Mol Cell Neurosci 43: 33-42 (2010).